HBsAg低且HBcrAg滴度高的HBV患者HBV相关性HCC风险较高

StephenW

Hepatol Res. 2018 Oct 22. doi: 10.1111/hepr.13277. [Epub ahead of print]
HBV patients with low HBsAg and high HBcrAg titers have a high risk of HBV-related HCC.
Suzuki Y1, Maekawa S1, Komatsu N1, Sato M1, Tatsumi A1, Miura M1, Matsuda S1, Muraoka M1, Nakakuki N1, Shindo H1, Amemiya F1, Takano S1, Fukasawa M1, Nakayama Y1, Yamaguchi T1, Inoue T1, Sato T1, Sakamoto M1, Yamashita A2, Moriishi K2, Enomoto N1.
Author information

1
    First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, 1110, Shimokato, Chuo, Yamanashi, 409-3898, Japan.
2
    Department of Microbiology, University of Yamanashi, 1110, Shimokato, Chuo, Yamanashi, 409-3898, Japan.

Abstract
BACKGROUND AND AIM:

Although the viral markers HBsAg and HBcrAg may reflect intrahepatic hepatitis B virus (HBV) replication activity and may constitute important biomarkers for hepatocellular carcinoma (HCC), the value of using these two markers in combination for assessing the HCC risk has not been clarified in detail until now.
PATIENTS AND METHODS:

Four hundred and forty-nine consecutive patients with chronic HBV infection were included in the study and the association of HBsAg and HBcrAg with the HCC risk was investigated cross-sectionally, as well as longitudinally.
RESULTS:

When the high value cutoffs of HBsAg and HBcrAg were respectively defined as 3.0 LogIU/ml and 3.0 LogU/ml, patients with a history of HCC were found frequently in the low HBsAg group (p=0.002) and high HBcrAg group (p<0.001). When HBsAg and HBcrAg were combined, an HCC history was most frequent in the subset with low HBsAg and high HBcrAg, among the HBeAg negative patients (OR 7.83, p <0.001), irrespective of nucleos(t) ide analogue (NA) administration (NA: OR 4.76, p <0.001, non-NA: OR 9.60, p <0.001). In a longitudinal analysis of the subsequent development of HCC, carried out on the 338 patients without an HCC history at enrollment, HCC developed significantly more frequently in the low HBsAg/high HBcrAg group (p = 0.005).
CONCLUSIONS:

The low HBsAg/high HBcrAg value group is at high risk of developing HBV-related HCC, according to cross-sectional and longitudinal analysis, demonstrating that the combination of HBsAg and HBcrAg values is an excellent biomarker for assessing the HCC risk.

This article is protected by copyright. All rights reserved.
KEYWORDS:

HBV; HBcrAg; HBsAg; HCC; Nucleot(s) ide analogue therapy

PMID:
    30350374
DOI:
    10.1111/hepr.13277

StephenW

Hepatol Res。 2018年10月22日。土井：10.1111 / hepr.13277。 [提前打印]
HBsAg低且HBcrAg滴度高的HBV患者HBV相关性HCC风险较高。
Suzuki Y1，Maekawa S1，Komatsu N1，Sato M1，Tatsumi A1，Miura M1，Matsuda S1，Muraoka M1，Nakakuki N1，Shindo H1，Amemiya F1，Takano S1，Fukasawa M1，Nakayama Y1，Yamaguchi T1，Inoue T1，Sato T1 ，Sakamoto M1，Yamashita A2，Moriishi K2，Enomoto N1。
作者信息

1
    山梨大学医学部第一内科，日本山梨县中央区下川1110号，邮编：409-3898。
2
    山梨大学微生物学系，山梨县中央区1110，山梨县，邮编：409-3898，日本。

抽象
背景和目的：

尽管病毒标志物HBsAg和HBcrAg可能反映肝内乙型肝炎病毒（HBV）复制活性，并可能构成肝细胞癌（HCC）的重要生物标志物，但将这两种标志物联合用于评估HCC风险的价值尚未详细阐明到现在。
患者和方法：

本研究纳入了连续449例慢性HBV感染患者，并对HBsAg和HBcrAg与HCC风险的关系进行了横断面和纵向调查。
结果：

当HBsAg和HBcrAg的高值截止值分别定义为3.0 LogIU / ml和3.0 LogU / ml时，在低HBsAg组（p = 0.002）和高HBcrAg组（p <0.001）中常见有HCC病史的患者。 ）。当HBsAg和HBcrAg合并时，在HBeAg阴性患者（OR 7.83，p <0.001）中HBsAg低和HBcrAg高的子集中HCC史最常见，不论核苷（t）ide类似物（NA）给药（ NA：OR 4.76，p <0.001，非NA：OR 9.60，p <0.001）。在对HCC随后发展的纵向分析中，对入选时无HCC病史的338例患者进行了HCC，在低HBsAg /高HBcrAg组中HCC发生率明显更高（p = 0.005）。
结论：

根据横断面和纵向分析，低HBsAg /高HBcrAg值组具有发展HBV相关HCC的高风险，证明HBsAg和HBcrAg值的组合是评估HCC风险的优异生物标志物。

本文受版权保护。版权所有。
关键词：

HBV; HBcrAg;乙肝表面抗原; HCC; Nucleot（s）ide类似疗法

结论：
    30350374
DOI：
    10.1111 / hepr.13277